ADDF Diagnostics Accelerator Funding for FTD Biomarker Development
Funds innovative research to develop accessible and effective diagnostic biomarkers for frontotemporal degeneration, prioritizing peripheral and digital tools to advance FTD diagnosis.
Funder: The Association for Frontotemporal Degeneration
Due Dates (Anticipated): March 2027 (Letter of Intent) | May 2027 (Full Proposal)
Funding Amounts: Typical awards range from $250,000–$500,000 per project; larger awards considered with justification; duration up to 2 years.
Summary: Supports innovative research for biomarker development in frontotemporal degeneration (FTD) through a venture philanthropy partnership.
Key Information: All dates are projected; confirm on program page before applying.
Description
This program funds high-risk, high-reward research aimed at accelerating the development of diagnostic biomarkers for frontotemporal degeneration (FTD). Jointly launched by the Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD), the initiative leverages venture philanthropy to support projects that may not have immediate commercial potential but have strong potential to advance FTD diagnosis. Funding is available for innovative projects focused on peripheral and digital biomarkers, with the goal of making diagnostic tools more accessible and effective for FTD.
